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Abstract: Central neuropathic pain (central pain) is treated with antidepressants, various 
anticonvulsants, opioids, and cannabinoids, but in many cases treatment is insufﬁ  cient and 
associated with a range of side-effects. This review addresses a new treatment for neuropathic 
pain, the anticonvulsant pregabalin. We review the pharmacology, mode of action, pharma-
cokinetics, and safety of pregabalin as well as two randomized efﬁ  cacy studies in central pain 
and a brief overview of efﬁ  cacy in peripheral neuropathic pain. Pregabalin appears to have 
efﬁ  cacy in treating central pain comparable to that in peripheral neuropathic pain as well as 
efﬁ  cacy of other recommended drugs for central pain. Pregabalin also improves disturbed sleep 
and anxiety. Pregabalin is well tolerated; the most common side-effects are somnolence, diz-
ziness, ataxia, and weight gain. Pregabalin is suitable for patients on multiple drugs although 
there may be additive CNS-related side-effects. Thus, pregabalin has a primary role in central 
pain patients.
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Introduction
Central neuropathic pain (central pain) is pain caused by a disease or lesion in the central 
nervous system. Central pain develops in about 8% of stroke patients (Andersen et al 
1995), 25% of patients with multiple sclerosis (Osterberg et al 2005), and 40%–50% 
of patients with spinal cord injury (Budh et al 2003; Siddall et al 2003; Werhagen 
et al 2004) and may develop secondary to brain and spinal cord tumors and other 
diseases affecting the central nervous system. Central pain thus affects a large num-
ber of patients worldwide and often it has a substantial impact on the quality of life, 
mood, sleep, cognition, social relations, etc. Central pain is characterized by ongoing 
pain, which may be burning, squeezing, pricking, and shooting and/or evoked types 
of pain, eg, pain evoked by light touch. The pain is located within an area of sensory 
disturbance covering various proportions of the deafferented body regions. Treatment 
of central pain is often difﬁ  cult and requires a different approach than nociceptive 
pain. Central pain is usually treated with antidepressants, anticonvulsants, and opioids; 
treatments which provide partial pain relief at best and which are often associated 
with side-effects.
Pregabalin is a novel, centrally acting neuromodulating agent that was approved 
by the US Food and Drug Administration (FDA) in 2004 for the treatment of painful 
diabetic peripheral neuropathy and post-herpetic neuralgia. In 2005 it was approved 
as adjunctive therapy in adults with partial seizures and recently it has been approved 
for the treatment of ﬁ  bromyalgia. Pregabalin is approved by the European Medicines 
Agency (EMEA) for the treatment of peripheral and central neuropathic pain in 
adults, as adjunctive therapy in adults with partial seizures, and for the treatment of Neuropsychiatric Disease and Treatment 2007:3(6) 886
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generalized anxiety disorder (GAD) in adults (EMEA 2006; 
Pﬁ  zer 2007). The trade name of pregabalin is Lyrica®, mar-
keted by Pﬁ  zer.
Pregabalin pharmacology, mode 
of action and pharmacokinetics
Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid) 
is a structural derivative of the inhibitory neurotransmitter 
γ-aminobutyric acid (GABA). Pregabalin is structurally 
related to gabapentin and has a similar pharmacological proﬁ  le 
and anticonvulsant and analgesic activity (Ben-Menachem 
2004). The predominant mechanism of action is thought to 
be through its presynaptic binding to the α2δ subunit of volt-
age-gated calcium channels which in turns leads to reduced 
release of neurotransmitters, eg, glutamate, substance P, 
and calcitonin gene-related peptide (Fehrenbacher et al 
2003; Sills 2006; Li et al 2006; Dooley et al 2007; Taylor 
et al 2007). Such decrease in neurotransmitter release from 
synapses in several neuronal tissues in the spinal cord and 
brain is likely to attenuate neuronal hyperexcitability and 
abnormal synchronization and may thus explain its anticon-
vulsant, analgesic, and anxiolytic activity (Taylor et al 2007). 
Pregabalin does not appear to act through the GABAergic 
neurotransmitter system (reviewed in, eg, (Sills 2006) and 
(Taylor et al 2007)) and although it has been shown to act on 
voltage-gated potassium channels (McClelland et al 2004), 
this mechanism of action is not thought to contribute signiﬁ  -
cantly to the pharmacological proﬁ  le (Sills 2006).
Pregabalin has linear pharmacokinetics and a predictable 
dose-response relationship. The pharmacokinetic and safety 
properties of pregabalin have been studied in healthy subjects 
and patients with renal impairment (Randinitis et al 2003). 
The oral bioavailability is 90% and dose-independent, and 
pregabalin is rapidly absorbed in the fasting state with a Tmax 
of 1 hour which is reduced by food consumption by 35%. 
Food does not alter the area under the curve and has no clini-
cally signiﬁ  cant effect. Steady-state plasma concentration is 
obtained after 24–48 hours.
Pregabalin does not bind to plasma proteins and thus read-
ily penetrates the blood-brain barrier. Over 98% of pregabalin 
is excreted unchanged in urine. The elimination half-time is 
4.8–6.3 hours but is increased in patients with renal impair-
ment and dependent on the creatinine clearance. Therefore, 
dose reduction is needed in patients with impaired renal func-
tion (ie creatinine clearance 60 mL/min) (Randinitis et al 
2003) (Table 1). Data are lacking for elderly patients.
Pregabalin is not metabolized in the liver and has no effect 
on the cytochrome P450 system or other liver enzymes and 
has no plasma protein binding consistent with the lack of 
interactions with other anticonvulsants, certain antidiabetics, 
and oral contraceptives (Ben-Menachem 2004; Tassone et al 
2007). Additive adverse effects on cognitive and gross motor 
functioning have been seen with pregabalin co-administered 
with oxycodone, lorazepam, and ethanol, and concomitant 
treatment with pregabalin and a thiazolidinedione anti-
diabetic agent may lead to an additive effect on edema and 
weight gain (EMEA 2004; Pﬁ  zer 2007).
Efﬁ  cacy studies
Peripheral neuropathic pain
Pregabalin has in large published parallel-group design 
studies consistently been shown to relieve post-herpetic 
neuralgia (Dworkin et al 2003; Sabatowski et al 2004; 
Freynhagen et al 2005; van Seventer et al 2006) and pain-
ful diabetic neuropathy (Lesser et al 2004; Rosenstock et al 
2004; Freynhagen et al 2005; Richter et al 2005) with a 
combined number needed to treat (NNT) for doses ranging 
from 300 mg to 600 mg of 3.9 (3.3–4.7). For comparison, the 
NNT values in peripheral neuropathic pain are 2.3 (2.1–2.7) 
for tricyclic antidepressants, 2.7 (2.1–3.6) for opioids, 3.9 
(2.7–6.7) for tramadol, 4.4 (2.5–17) for topical lidocaine, and 
5.5 (3.4–14) for serotonin noradrenaline reuptake inhibitors, 
but differences in design and study population may make 
direct comparison of NNT values difﬁ  cult (Finnerup et al 
2005). The total number of patients included 1028 exposed 
to pregabalin and 575 to placebo in the 300–600 mg dose 
range. Two studies in painful diabetic neuropathy reported by 
the European Medicines Agency in 2004 (EMEA 2004) are 
still unpublished; one study including 396 patients showed 
efﬁ  cacy of pregabalin 300/600 mg daily, while a 3-armed 
study with pregabalin 600 mg (n = 87), amitriptyline 75 mg 
(n = 88) and placebo (n = 81) failed to show a signiﬁ  cant 
pain-relieving effect with pregabalin (p = 0.08). The dif-
ference in mean endpoint score between pregabalin and 
placebo for all peripheral neuropathic pain studies ranged 
Table 1 Pregabalin dosage adjustment based on renal function 
(Pﬁ  zer 2007)
Creatinine  Total pregabalin daily dose (mg)  Dose regiment
clearance
(mL/min)
60  150  300  600  bid or tid
30–60  75  150  300  bid or tid
15–30  25–50  75  150  qd or bid
15 25  25–50  75  qd
Abbreviations: tid, three divided doses; bid, two divided doses; qd, single daily 
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from −0.18 to −1.57 points for the 300 mg daily score and 
from −0.64 to −2.02 points for the 600 mg daily score (EMEA 
2004). There was no effect of pregabalin 75 mg daily and 
inconsistent efﬁ  cacy for 150 mg daily. Efﬁ  cacy was observed 
from week 1 and maintained throughout the study periods. 
The ﬁ  rst studies on pregabalin (Dworkin et al 2003; Lesser 
et al 2004; Rosenstock et al 2004; Sabatowski et al 2004) 
excluded patients who failed to respond to previous treatment 
with gabapentin, which may bias the efﬁ  cacy outcome mea-
sures in favor of pregabalin (Finnerup et al 2005), but more 
recent trials without this exclusion criterion have comparable 
NNT values (Freynhagen et al 2005; Richter et al 2005; van 
Seventer et al 2006). Somnolence is a frequent adverse event 
present in 20%–30% and subanalyses have shown that the 
pain relieving effect was larger in patients experiencing 
somnolence as an adverse effect (EMEA 2004). However, 
pregabalin still had a pain relieving effect in those patients 
not experiencing somnolence as an adverse effect (EMEA 
2004). The published clinical trials found dose-dependent 
efﬁ  cacy in pain relief as well as improvements in sleep and 
global impressions of changes (integrating the effect of treat-
ment and side-effects), and some studies also in quality of 
life measures (Lesser et al 2004; Sabatowski et al 2004) and 
mood (Rosenstock et al 2004).
Central pain
Two randomized placebo-controlled trials have been con-
ducted in central pain (Table 2). The ﬁ  rst study published is 
a parallel group design study in central neuropathic pain due 
to spinal cord injury (Siddall et al 2006). A baseline week was 
followed by a 3-week titration period where pregabalin was 
increased up to 300 mg bid and a 9-week ﬁ  xed dose period. 
Seventy patients were allocated to the pregabalin arm and 
76 to the placebo arm. Concurrent pain medication was kept 
constant during the trial and included tricyclic antidepressants 
in 33% in the pregabalin group and 18% in the placebo group, 
opioids in 30% and 48%, and antiepileptic drugs except gaba-
pentin in 11% and 9 % respectively. Muscle relaxants (includ-
ing baclofen) were used by 54% in the pregabalin group and 
37% in the placebo group while benzodiazepines were used 
by 40% and 39% respectively. The mean pregabalin dose 
during the ﬁ  xed dose period was 460 mg/day. Pain was 
evaluated daily on a numeric rating scale (NRS, 0–10) and the 
primary efﬁ  cacy measure was the weekly mean pain score at 
endpoint (last week on study drug). The improvement in pain 
score from baseline (pregabalin – placebo) was −1.53 (−0.92 
to −2.15), similar to values observed in studies in peripheral 
neuropathic pain. The effect was signiﬁ  cant from week 1 and 
remained so for the duration of the study. Pregabalin also 
improved pain-related sleep interference and anxiety. The 
NNT for 50% pain relief (7.1 (3.9–37)) was higher than in 
most peripheral neuropathic pain studies; however, the NNT 
for 30% pain relief (3.9 (2.5–9.1)) and pain improvement on 
the patient global impression of change (2.9 (20–5.1)) was 
similar to what is observed in post-herpetic neuralgia and 
painful diabetic neuropathy (Lesser et al 2004; Rosenstock 
et al 2004; Sabatowski et al 2004; Freynhagen et al 2005; 
van Seventer et al 2006).
Recently, pregabalin was studied in a parallel group 
design study in patients with central pain following stroke 
or spinal cord injury (Vranken et al 2007). The etiology was 
stroke in 19 patients (of these thalamic lesion in 4 and brain-
stem infarction in 3) and spinal cord injury in 21 patients (of 
these 11 had a complete injury). The diagnoses were evenly 
distributed among patients allocated to pregabalin (n = 20) 
and to placebo (n = 20). For the diagnosis of central pain, the 
pain should be described as burning, paroxysmal episodes 
of shooting pain, or pain on light touch, and patients had to 
score above 12 on the Leeds Assessment of Neuropathic 
Symptoms and Signs questionnaire (LANSS) (Bennett 2001). 
A baseline pain score above 6 (visual analog scale, VAS) 
was required. In a ﬂ  exible-dose regime and with no base-line 
period, patients received escalating doses of either pregabalin 
tablets 150 mg or matching placebo capsules bid titrated at 
3-day intervals until a pain reduction of 1.8 on a VAS was 
obtained, they reached the maximum daily dose of 600 mg, 
or had intolerable side-effects. The patients then remained on 
the ﬁ  nal dose during the remainder of the study period, which 
Table 2 Randomized placebo-controlled trials of pregabalin in central pain
Study Population  Design  Daily  dose  NNT  
        50% pain relief  30% pain relief
Siddall et al 2006  Spinal cord injury pain (n = 70)  Parallel  Up to 600 mg,  7.1 (3.9–37)  3.9 (2.5–9.1)
      average 460 mg
Vranken et al 2007  Spinal cord injury pain and  Parallel  Up to 600 mg,  3.3 (1.9–14.3)  4.0 (2.0–328)
  central post-stroke pain (n = 40)    average 460 mg
Abbreviation: NNT, number needed to treat.Neuropsychiatric Disease and Treatment 2007:3(6) 888
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was 4 weeks. Patients treated with gabapentin discontinued 
this treatment at least 3 days before receiving study medica-
tion. Pain medication that was continued during the trial was 
opioids in 53%, antidepressants in 30%, and carbamazepine 
in 10%. Baclofen was used by 10%. Seventeen patients in the 
pregabalin group completed the study: nine received 600 mg 
and eight received 300 mg daily. The primary efﬁ  cacy param-
eter was the pain intensity based on the average of 3 VAS 
pain scores measured during the 24 hours prior to baseline 
and at the end of the 4-week treatment period. The improve-
ment in pain score from baseline (pregabalin – placebo) was 
−2.18 (−0.57 to −3.80) with no difference in efﬁ  cacy between 
the groups with spinal and brain injury. The NNT for 50% 
pain relief was low, 3.3 (1.9–14.3), and for 30% pain relief 
it was 4.0 (2.0–328).
In both studies, pregabalin was an add-on analgesic, 
which suggests that responses may be due to synergistic 
interactions. In painful diabetic neuropathy pregabalin was 
effective as monotherapy (Lesser et al 2004; Rosenstock 
et al 2004; Richer et al 2005), and in both studies in central 
pain, effect sizes were similar regardless of whether patients 
used any concomitant analgesics (Siddall et al 2004; Vranken 
et al 2007). This would suggest that pregabalin is effective 
as monotherapy also in central pain, but potential syner-
gistic effects need to be studied in appropriately designed 
studies.
Safety and tolerability
Pregabalin is generally well tolerated with no contraindica-
tions except for known hypersensitivity to pregabalin or 
its components. The most common adverse reactions in 
the peripheral neuropathic pain studies were dose-related 
dizziness (22%–38%) and somnolence (11%–25%), which 
does not resolve in about one third of patients. These side-
effects pose a risk for accidental injury in the elderly. Other 
adverse reactions were dry mouth, asthenia, blurred vision, 
ataxia, peripheral edema, and weight gain not limited to 
patients with edema. Adverse events were usually mild or 
moderate. There are little data on withdrawal phenomena. 
In short term trials pregabalin treatment is not associated 
with clinical signiﬁ  cant withdrawal syndromes (Frampton 
and Foster 2006), but abrupt discontinuation may cause 
insomnia, nausea, headache, or diarrhea and it is recom-
mended to taper off during at least one week (Pﬁ  zer 2007). 
In case of persistent blurred vision, a visual ﬁ  eld testing and 
funduscopic examination may be considered, and patients 
are advised to report unexplained muscle pain particularly 
if accompanied with malaise and fever (Pﬁ  zer 2007) due 
to unsettled relation of pregabalin to rhabdomyolysis and 
creatine kinase elevations. Pregabalin is recommended to be 
used with caution in patients with congestive heart failure 
(NYHA, (New York Heart Association) class III and IV) 
because of limited data in this population (Pﬁ  zer 2007).
In the two studies in central pain, patients with a cre-
atinine clearance below 60 mL/min were excluded. The 
frequency of somnolence in the trial by Siddall et al (2006) 
(41% in the pregabalin group and 9% in the placebo group) 
was more common than in studies in peripheral neuropathic 
pain, which may be attributed to additive effects of concomi-
tant medications such as baclofen and benzodiazepines in 
this patient population. In the study by Vranken et al (2007), 
somnolence occurred in 45% but was equally common in 
the placebo group. Other more frequent adverse reactions in 
the pregabalin group in the Siddall study included: dizziness 
observed in 24%, edema in 20%, asthenia and dry mouth each 
in 16%, constipation in 13%, amnesia in 10%, and blurred 
vision in 9%. The frequency of peripheral edema (10%) was 
not higher than that observed in peripheral neuropathic pain. 
Two patients in the placebo group and eight in the pregabalin 
group had a weight gain 7%. The median time to onset 
of somnolence and dizziness was within 8 and 6 days and 
lasted 53 days and 33 days respectively. Adverse reactions 
were generally mild to moderate. Withdrawal due to side-
effects occurred in 15 pregabalin- and 9 placebo-treated 
patients. Two adverse reactions were considered related to 
treatment: one had a withdrawal reaction 1 day following 
pregabalin discontinuation with increased spasticity and 
impaired coordination, and one had edema, hypervolemia and 
reduced platelet count caused by an infection. In the study 
by Vranken et al (2007), side-effects were mild to moder-
ate with no difference in frequency of adverse reactions in 
the two study groups. Withdrawal due to adverse reactions 
occurred in 3 patients in each group.
Discussion
Few other randomized trials have been performed in central 
pain (Finnerup and Sindrup 2007). The related drug gabap-
entin has been studied in spinal cord injury pain (Levendoglu 
et al 2004). Gabapentin up to 3600 mg relieved intensity 
and frequency of pain and several pain descriptors in 20 
paraplegics with complete spinal cord injury. The tricyclic 
antidepressant (TCA) amitriptyline has been studied in a 
three-way crossover study in post-stroke pain (Leijon and 
Boivie 1989). Amitriptyline in doses up to 75 mg daily had 
a signiﬁ  cant pain-relieving effect, which correlated with 
total plasma concentration. Amitriptyline did not relieve Neuropsychiatric Disease and Treatment 2007:3(6) 889
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nociceptive and neuropathic pain in spinal cord injury, but 
neuropathic pain was not evaluated separately (Cardenas et al 
2002). The anticonvulsant and sodium blocker lamotrigine 
reduced central post-stroke pain in doses of 200 mg/day as 
well as cold allodynia (Vestergaard et al 2001), but in spinal 
cord injury pain, lamotrigine 200–400 mg daily was not more 
effective than placebo in reducing pain, although a post-hoc 
analysis suggested that it may be effective in a subgroup of 
patients with incomplete injury and evoked pain (Finnerup 
et al 2002). In multiple sclerosis, cannabinoids have been 
shown to relieve central pain (Svendsen et al 2004; Rog 
et al 2005). Opioids also relieve central pain (Rowbotham 
et al 2003). Carbamazepine did not relieve post-stroke pain 
(Leijon and Boivie 1989) and mexiletine (Chiou-Tan et al 
1996) and valproate (Drewes et al 1994) had no signiﬁ  cant 
effect in spinal cord injury pain, but these studies all include 
a low number of patients with a risk of a type II error.
Treatment of central and peripheral neuropathic pain is 
limited by side-effects and high potential for drug interaction. 
Side-effects to TCAs attributed to anticholinergic actions are 
common, eg, dry mouth, constipation, and urinary retention, 
and there is a risk of somnolence and confusion, orthostatic 
hypotension, and gait disturbances. The most serious side 
effect is cardiotoxicity (Ray et al 2004), and TCAs are con-
traindicated in patients with heart failure and cardiac conduc-
tion blocks, and ECG is therefore needed before initiating 
treatment. Lamotrigine treatment is associated with dizziness, 
ataxia, diplopia, somnolence, nausea, and allergic exanthema 
and Stevens-Johnson syndrome, and very slow-dose escala-
tion is recommended. Side-effects to cannabinoids include 
dizziness, drowsiness, impaired psychomotor function, and 
other psychoactive effects like dysphoria, and there is an 
unsettled issue with respect to risk of precipitating psychosis 
or schizophrenia (Semple et al 2005). The most common 
adverse effects of opioids are sedation, constipation, and 
nausea. Other side-effects include confusion, especially in 
elderly patients, urinary retention, dizziness, and dysphoria 
as well as risk of abuse and addiction. It is therefore recom-
mended to consider long-term opioids for non-cancer pain 
only when other reasonable therapies fail to provide adequate 
pain relief (Kalso et al 2003).
In summary, amitriptyline (central post-stroke pain), 
lamotrigine (central post-stroke pain but a negative trial in 
spinal cord injury pain), gabapentin (spinal cord injury pain), 
and pregabalin (spinal cord injury and central post-stroke 
pain), and cannabinoids (central pain in multiple sclerosis) 
have proven to be effective, but large-scale randomized 
controlled studies are lacking, and a treatment algorithm 
for central pain still needs to be based partly on established 
treatments for peripheral neuropathic pain for which TCAs, 
serotonin-noradrenaline reuptake inhibitors, gabapentin/
pregabalin, and opioids/tramadol have consistently shown 
efﬁ  cacy (Finnerup et al 2005). There is no evidence to sug-
gest that pregabalin and gabapentin have different efﬁ  cacy 
or side effects determined by NNT or NNH values (Finnerup 
et al 2005). Differences between the two drugs relates to 
slightly higher expenses for pregabalin at the moment but 
more favorable dosing (twice daily dose possible) and linear 
kinetics with pregabalin. Thus, based on evidence for efﬁ  -
cacy, gabapentin, pregabalin, and TCAs consistently relieve 
peripheral neuropathic pain as well as central pain (except 
for the lack of efﬁ  cacy of amitriptyline in spinal cord injury 
mixed pain). Of these, gabapentin and pregabalin may be 
considered the ﬁ  rst-line drugs for the treatment of central pain 
due to their consistent efﬁ  cacy, safety, and minimal potential 
for drug-drug interactions, and TCAs a second line-treatment 
if no contraindications exist. Possible third-line treatments for 
central pain include opioids and tramadol, cannabinoids in 
multiple sclerosis, lamotrigine, and serotonin-noradrenaline 
reuptake inhibitors, which have not yet been tested in central 
pain but have a better side-effect proﬁ  le than TCAs. In many 
cases, treatment provides no or only partial pain relief, and 
often combination therapy is used. There is a strong rational 
for combining drugs with different mode of actions (Backonja 
et al 2006), but little clinical evidence. In one randomized 
trial, gabapentin and morphine combined achieved better 
analgesia at lower doses than with either drug alone (Gilron 
et al 2005).
The recommended dose of pregabalin is 75–150 mg twice 
daily or 50–100 mg 3 times a day in patients with a creatinine 
clearance of at least 60 mL/min. Dosing is usually started 
at 75 mg once or twice daily and may be increased to 300 
mg/ day within 1 week based on efﬁ  cacy and tolerability. 
Dose may be increased up to 600 mg daily after yet another 
2–4 weeks. Patients with post-stroke pain may be more 
susceptible to medication than other patient populations. 
For that reason it is advisable in some patients to start with 
a low pregabalin dose of 25 mg and increase slowly. The 
dose should be adjusted for patients with renal impairment 
(Table 1). There are limited data on long-term efﬁ  cacy and 
adherence.
Conclusion
Based on efﬁ  cacy and safety, pregabalin is considered a 
ﬁ  rst-line drug together with gabapentin in the treatment of 
central pain. Pregabalin and gabapentin may especially have Neuropsychiatric Disease and Treatment 2007:3(6) 890
Finnerup and Jensen
a primary role in patients with anxiety and sleep disturbances 
and in patients who are taking multiple drugs. Somnolence, 
dizziness, and accidental falls may be a concern, especially 
in the elderly and in those treated with other drugs with 
CNS-related side-effects.
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